Ipsen Pharma: Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs Ipsen will now lead all development

Related Keywords

Saclay ,France General ,France ,Shanghai ,China ,Paris ,Montreal ,Quebec ,Canada ,Cambridge ,Cambridgeshire ,United Kingdom ,Alix Molinier ,Desbois Mackenzie ,Ipsen Euronext ,Christelle Huguet ,Jess Smith ,Claude Larose ,Ioana Piscociu ,Michel Bouvier ,Vp Business Development ,Centre Of Excellence ,Global Partnering Communications ,Institute For Research ,Ipsen Iricor Press ,Innovation Early Development At Ipsen ,External Innovation ,Early Development ,Director General ,Rare Disease ,French Autorit ,Des March ,Registration Document ,Global Media ,Marcel Torney ,Lipsen ,Dharma ,Universit 233 ,Ontr 233 Al ,Tricor ,Broaden ,Xisting ,Ncology ,Partnership ,Exclusive ,License ,Agreement ,Discovery ,Stage ,Programs ,